Lurbinectedin单药或联合化疗治疗转移性/不可切除软组织肉瘤的II期多分层研究
这项三臂II期研究评估了Lurbinectedin单药或联合化疗在转移性/不可切除软组织肉瘤中的疗效,主要终点为24周疾病控制率。A层(Lurbinectedin/多柔比星)达到终点,ORR 35.0%,24周DCR 40.0%;B层和C层未达到主要终点。中位PFS分别为A层4.2个月、B层1.7个月、C层1.3个月,血液学不良事件最常见,无治疗相关死亡。
要点
- Lurbinectedin联合多柔比星在蒽环类未治患者中达到主要终点,ORR 35.0%,24周DCR 40.0%。
- Lurbinectedin单药或联合吉西他滨在经治患者中未达到主要终点。
- 药物在平滑肌肉瘤、去分化脂肪肉瘤、黏液样脂肪肉瘤、滑膜肉瘤和促结缔组织增生性小圆细胞肿瘤中显示获益证据。
核心结论
- Lurbinectedin联合多柔比星在蒽环类未治的转移性/不可切除软组织肉瘤中达到24周DCR主要终点,ORR为35.0%,24周DCR为40.0%。
- Lurbinectedin联合吉西他滨和单药在经治患者中未达到主要终点。
研究设计与样本
- 入组患者为成人转移性/不可切除软组织肉瘤,既往细胞毒治疗≤2线。
- A层(蒽环类未治)接受Lurbinectedin/多柔比星;B层(既往蒽环类)接受Lurbinectedin/吉西他滨;C层(既往蒽环类和吉西他滨)接受Lurbinectedin单药。
主要发现
- A层有7例部分缓解和1例24周疾病稳定。
- B层有2例达到24周疾病控制,包括1例部分缓解(平滑肌肉瘤)和1例疾病稳定(促结缔组织增生性小圆细胞肿瘤)。
- C层无患者达到主要终点。
- 中位PFS:A层4.2个月(90% CI 1.4-7.8),B层1.7个月(90% CI 1.0-7.4),C层1.3个月(90% CI 1.1-3.0)。
- 常见毒性为血液学不良事件,无治疗相关死亡。
关键数值与推荐
- A层:ORR 35.0%,24周DCR 40.0%(7例PR和1例SD)。
- B层:2例达到24周DCR(1例PR和1例SD),未继续第二阶段。
- C层:无患者达到24周DCR主要终点。
临床怎么用
- Lurbinectedin联合多柔比星可作为蒽环类未治软组织肉瘤患者的潜在选择,但需进一步研究确认。
- Lurbinectedin联合吉西他滨或单药在经治患者中未显示足够疾病控制,不支持常规使用。
局限性
- 样本量小,各分层患者数有限(A层20例、B层10例、C层12例)。
- B层未继续进入第二阶段,可能影响该方案的疗效评估。
- 研究为II期单臂分层设计,需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemotherapy objective response rates (ORRs) in metastatic soft tissue sarcoma (STS) are typically 20-40% with median progression-free survival (PFS) less than 6 months. Lurbinectedin is a new anticancer agent under investigation. The primary objective of this three-arm, phase II study was to determine the disease control rate (DCR = ORR + stable disease [SD]) at 24 weeks of lurbinectedin alone or with chemotherapy in STS. Eligible patients included adults with ≤2 prior cytotoxic therapies. Study cohorts were: stratum A (StrA; anthracycline-naive), lurbinectedin/doxorubicin; stratum B (StrB; prior anthracycline), lurbinectedin/gemcitabine; stratum C (StrC; prior anthracycline/gemcitabine) lurbinectedin monotherapy. Each stratum was analysed separately by Simon two-stage design. Forty-two patients were accrued (StrA = 20, StrB = 10, StrC = 12) including leiomyosarcoma [LMS] (n = 20), synovial sarcoma [SS](n = 4), malignant peripheral nerve sheath tumour (n = 3) and other STS histologies (n = 15). For StrA there were seven partial responses (PR) plus one stable disease (SD) at 24 weeks. For StrB, two patients met the 24-week DCR including one PR (leiomyosarcoma) and one SD (desmoplastic small round cell tumour [DSRCT]). StrB did not continue to the second stage. In StrC, no patients met the primary end-point. Median progression-free survival (PFS) was: StrA = 4.2 months (90% CI 1.4-7.8), StrB = 1.7 months (90% confidence interval (CI) 1.0-7.4), and StrC = 1.3 months (90% CI 1.1-3.0). Lurbinectedin as a single agent or with chemotherapy was well tolerated with haematologic adverse events (AE's) as the most common toxicity. There were no treatment-related deaths. The combination of lurbinectedin/doxorubicin reached the DCR end-point with seven PR and one patient with SD (ORR 35.0%, 24-week DCR 40.0%). Evidence of drug benefit was seen in leiomyosarcoma, dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), synovial sarcoma (SS), and desmoplastic small round cell tumour (DSRCT). TRIAL REGISTRATION: clinicaltrials.gov; NCT02448537.
引用
- Cote GM, Choy E, Chen T, et al. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2019. PMID: 31896519. doi:10.1016/j.ejca.2019.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。